PE20231679A1 - Metodos para la deteccion de anticuerpos antifarmaco contra anticuerpos de factor xi y/o factor xia - Google Patents

Metodos para la deteccion de anticuerpos antifarmaco contra anticuerpos de factor xi y/o factor xia

Info

Publication number
PE20231679A1
PE20231679A1 PE2023001878A PE2023001878A PE20231679A1 PE 20231679 A1 PE20231679 A1 PE 20231679A1 PE 2023001878 A PE2023001878 A PE 2023001878A PE 2023001878 A PE2023001878 A PE 2023001878A PE 20231679 A1 PE20231679 A1 PE 20231679A1
Authority
PE
Peru
Prior art keywords
factor
antibodies
methods
antidrug
xia
Prior art date
Application number
PE2023001878A
Other languages
English (en)
Inventor
Debra A Freedholm
Daniel M Bloomfield
Royston J Glasspool
Jonathan E Freeman
Yasser Khder
Original Assignee
Anthos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anthos Therapeutics Inc filed Critical Anthos Therapeutics Inc
Publication of PE20231679A1 publication Critical patent/PE20231679A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96452—Factor XI (3.4.21.27)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Esta referida a metodos para detectar y determinar los anticuerpos antifarmaco (ADA) contra los anticuerpos terapeuticos Factor XI y/o Factor XIa, por ejemplo, en un sujeto que recibe tratamiento con dichos anticuerpos terapeuticos Factor XI y/o Factor XIa. Este metodo comprende: (a) incubar una muestra con un acido para disociar los complejos de antigeno y anticuerpo anti-Factor XI y/o anti-Factor XIa y/o disociar complejos de los ADA y del anticuerpo anti-Factor XI y/o anti-Factor XIa presentes en la muestra para formar una solucion de digestion acida, (b) incubar la solucion de digestion acida en una placa recubierta con el anticuerpo antiFactor XI y/o anti-Factor XIa o un fragmento de union a antigeno de este, (c) neutralizar la solucion de digestion acida, y (d) detectar la presencia de los ADA mediante el uso de un coctel de detectores rutenilados.
PE2023001878A 2020-12-18 2021-12-17 Metodos para la deteccion de anticuerpos antifarmaco contra anticuerpos de factor xi y/o factor xia PE20231679A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063127536P 2020-12-18 2020-12-18
PCT/US2021/064117 WO2022133263A1 (en) 2020-12-18 2021-12-17 Methods for the detection of anti-drug antibodies against factor xi and/or factor xia antibodies

Publications (1)

Publication Number Publication Date
PE20231679A1 true PE20231679A1 (es) 2023-10-19

Family

ID=82059801

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023001878A PE20231679A1 (es) 2020-12-18 2021-12-17 Metodos para la deteccion de anticuerpos antifarmaco contra anticuerpos de factor xi y/o factor xia

Country Status (18)

Country Link
US (1) US20240077497A1 (es)
EP (1) EP4264278A1 (es)
JP (1) JP2023554347A (es)
KR (1) KR20230121120A (es)
CN (1) CN116601491A (es)
AR (1) AR124434A1 (es)
AU (1) AU2021401421A1 (es)
CA (1) CA3199482A1 (es)
CL (1) CL2023001709A1 (es)
CO (1) CO2023008150A2 (es)
CR (1) CR20230313A (es)
CU (1) CU20230031A7 (es)
EC (1) ECSP23053645A (es)
IL (1) IL302904A (es)
MX (1) MX2023007281A (es)
PE (1) PE20231679A1 (es)
TW (1) TW202242414A (es)
WO (1) WO2022133263A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240027432A1 (en) * 2022-07-13 2024-01-25 Regeneron Pharmaceuticals, Inc. Mild acid immunoassays for detection of analytes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200312A1 (ar) * 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
US20200308301A1 (en) * 2017-11-22 2020-10-01 Novartis Ag Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
WO2019105916A1 (en) * 2017-11-29 2019-06-06 F. Hoffmann-La Roche Ag Target interference suppressed anti-drug antibody assay
JP2022532503A (ja) * 2019-05-13 2022-07-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 改善された競合的リガンド結合アッセイ

Also Published As

Publication number Publication date
KR20230121120A (ko) 2023-08-17
JP2023554347A (ja) 2023-12-27
CR20230313A (es) 2023-08-18
MX2023007281A (es) 2023-09-04
TW202242414A (zh) 2022-11-01
AU2021401421A1 (en) 2023-06-22
CN116601491A (zh) 2023-08-15
IL302904A (en) 2023-07-01
CL2023001709A1 (es) 2023-11-17
CA3199482A1 (en) 2022-06-23
AR124434A1 (es) 2023-03-29
EP4264278A1 (en) 2023-10-25
WO2022133263A1 (en) 2022-06-23
ECSP23053645A (es) 2023-08-31
US20240077497A1 (en) 2024-03-07
CO2023008150A2 (es) 2023-06-30
CU20230031A7 (es) 2024-02-07

Similar Documents

Publication Publication Date Title
Pawelec et al. The conundrum of human immune system “senescence”
Ramachandran et al. Activity-dependent degradation of the nascentome by the neuronal membrane proteasome
Kreiling et al. Age‐associated increase in heterochromatic marks in murine and primate tissues
PE20231679A1 (es) Metodos para la deteccion de anticuerpos antifarmaco contra anticuerpos de factor xi y/o factor xia
RU2011141499A (ru) Способ определения пола птиц
Monneret et al. How clinical flow cytometry rebooted sepsis immunology
IN2014MN01572A (es)
AR103935A1 (es) Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th-2
RU2014115999A (ru) Способ мониторинга, диагностики и/или прогнозирования острого повреждения почек на ранней стадии
MX2021010984A (es) Analizador de concentracion en el punto de atencion.
ES2530734T3 (es) Biomarcador en suero bioquímico
CO2018004289A2 (es) Inmunoensayo para detectar quininógeno escindido de alto peso molecular
PE20141450A1 (es) Ensayo de lisiloxidasa-homologo 2 y metodos de uso del mismo
MX2009011228A (es) Deteccion de niveles elevados de la proteina her-2/neu de celulas cancerosas circulantes no aisladas y tratamiento.
WO2018213641A8 (en) NMR METHODS AND SYSTEMS FOR RAPID DETECTION OF CANDIDA SPECIES
CN104232739A (zh) 枸橼酸原料中细菌内毒素的检测方法
CY1124409T1 (el) Μεθοδος μη επεμβατικης προγεννητικης ανιχνευσης της ανευπλοειδιας του εμβρυικου χρωμοσωματος απο το μητρικο αιμα με βαση τη μεθοδο του βayes
Wang et al. Determination of role of thromboxane A2 in rheumatoid arthritis
Ploquin et al. Systemic DPP4 activity is reduced during primary HIV‐1 infection and is associated with intestinal RORC+ CD4+ cell levels: a surrogate marker candidate of HIV‐induced intestinal damage
Vasquez-Rios et al. Evaluating the role of intestinal parasites in the high rates of irritable bowel syndrome in South America: a pilot study
MX2020009363A (es) Un método para detectar magea4.
EP4269987A3 (en) Systems and methods for normalizing signals in blood culture measurement systems
Wang et al. Detection of phosphatidylserine in the plasma membrane of single apoptotic cells using electrochemiluminescence
BR112023003553A2 (pt) Assinatura de localização celular e imunoterapia
BR112018006767A2 (pt) kit e métodos para a detecção rápida da ausência ou presença de uma ss-lactamase em amostras de fluidos corporais